Organigram Enters $65.2M Financing Agreement with British American Tobacco
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Organigram Global (OGI) announced that it has entered into a subscription agreement with BT DE Investments, a wholly-owned subsidiary of British American Tobacco (BTI), in connection with its previously announced proposed acquisition of Sanity Group, including shares of Sanity owned by BAT. The terms of the Subscription Agreement provide for the subscription by BAT for 14,027,074 shares of Organigram at a price of C$3.00 per share, for gross proceeds of C$42.08M, and also the exercise of certain existing top-up rights to subscribe for 9,897,356 Shares at a price of C$2.335854 per share, for gross proceeds of C$23.12M and for total gross proceeds of C$65.2M. ATB Financial is acting as sole lead arranger and bookrunner.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGI
Wall Street analysts forecast OGI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.430
Low
2.36
Averages
2.64
High
2.91
Current: 1.430
Low
2.36
Averages
2.64
High
2.91
About OGI
Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organigram Launches New Products in Australia
- Market Expansion: Organigram's launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia signifies an expansion of its international product portfolio, expected to meet rising market demand and enhance its global medical cannabis presence.
- Product Innovation: The new lineup includes 10 SKUs, with Edison vapes featuring single-strain live terpenes from Canada's top-selling cultivars, aimed at providing consistent dosing and convenient usage, reflecting the company's expertise in non-flower product development.
- Strategic Partnership: Through its distribution partnership with Leafio, Organigram's products are expected to reach over 4,000 pharmacies, enhancing accessibility and brand influence in the Australian market, thereby driving sales growth.
- Industry Event: Organigram will debut its new product lineup at the Medical Cannabis Symposium in Brisbane, using this platform to introduce its product portfolio to clinicians and industry participants, further solidifying its leadership position in the medical cannabis sector.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Organigram Secures CAD 65.2 Million Investment
- Investment Confirmation: Organigram Global Inc. confirmed a CAD 65.2 million private placement investment from a subsidiary of British American Tobacco, indicating strengthened financial health and increased market confidence.
- Financing Details: The financing includes the subscription of 14,027,074 shares at CAD 3.00 per share (totaling CAD 42.08 million) and the exercise of top-up rights for 9,897,356 shares at CAD 2.335854 per share (totaling CAD 23.12 million), culminating in gross proceeds of CAD 65.2 million.
- Market Reaction: Following the investment confirmation, Organigram's stock rose 8.70% in Thursday's premarket trading, reflecting investor optimism about the company's future, while the stock is currently trading 4.8% above its 20-day simple moving average.
- Earnings Outlook: Organigram is set to provide its next financial update on May 11, 2026, with EPS estimates dropping from 22 cents to a loss of 1 cent, while revenue estimates are expected to rise from CAD 45.70 million to CAD 54.67 million, indicating potential value opportunities.
See More
British American Tobacco Invests C$65.2M in Organigram Acquisition
- Investment Scale: British American Tobacco's C$65.2M private placement for Organigram's Sanity Group acquisition underscores its commitment to emerging markets, likely enhancing Organigram's competitive position.
- Share Subscription: Under the agreement, BAT will subscribe to approximately 14.02 million Organigram shares at C$3.00 each, generating about C$42.1M, which will further solidify its equity stake in Organigram.
- Use of Funds: The proceeds from this financing will be combined with existing cash and up to C$60M in credit facilities from ATB Financial to fund the cash portion of the Sanity acquisition and cover transaction costs, ensuring a smooth acquisition process.
- Market Reaction: Organigram's shares rose by 4.35% in premarket trading, reflecting positive market sentiment towards this investment and acquisition plan, which may enhance the company's long-term growth potential.
See More
Organigram Enters Subscription Agreement with BAT for Sanity Acquisition
- Significant Financing: Organigram's subscription agreement with BAT will provide the company with a total of C$65 million in funding, including the purchase of 14,027,074 shares at C$3.00 each, indicating strong market support for its acquisition of Sanity Group.
- Equity Structure Adjustment: BAT will receive 2,353,379 common shares and 21,571,051 preferred shares in this transaction, with the preferred shares convertible into common shares without exceeding a 30% ownership threshold, ensuring BAT's influence within the company.
- Regulatory Approval Requirements: The acquisition and private placement investment are subject to multiple regulatory approvals, including from the Toronto Stock Exchange and Organigram's shareholders, highlighting the complexity of the transaction and its implications for corporate governance.
- Strategic Investment Intent: Through this transaction, BAT further solidifies its investment in Organigram, reflecting its long-term optimism about the cannabis market and potentially increasing its control over the company by adding board members.
See More
Organigram Proposes Acquisition of Sanity Group
- Acquisition Overview: Organigram plans to acquire German cannabis company Sanity Group for €113.4 million (approximately $134 million), comprising €80 million in cash and €33.4 million in Organigram shares, significantly enhancing its position in the global cannabis market.
- Financing Strategy: The acquisition will be financed through a combination of cash on hand, proceeds from a new credit facility, and expected equity investment, with Organigram in talks for a CAD 65.2 million (around $47.8 million) investment from British American Tobacco to support the cash component of the deal.
- Strategic Importance: Paolo De Luca, Chief Strategy Officer, stated that by combining strengths with Sanity, Organigram will accelerate growth in key European markets and create substantial value for shareholders, thereby strengthening its competitive edge in the world's largest federally legal cannabis markets.
- Market Performance Analysis: Despite a 7.09% increase in premarket trading to $1.36, Organigram's stock remains below its 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, with key support at $1.00 and resistance at $1.50.
See More
Organigram Launches New Products in Australia
- Market Expansion: Organigram's launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia signifies an expansion of its international product portfolio, expected to meet rising market demand and enhance its global medical cannabis presence.
- Product Innovation: The new lineup includes 10 SKUs, with Edison vapes featuring single-strain live terpenes from Canada's top-selling cultivars, aimed at providing consistent dosing and convenient usage, reflecting the company's expertise in non-flower product development.
- Strategic Partnership: Through its distribution partnership with Leafio, Organigram's products are expected to reach over 4,000 pharmacies, enhancing accessibility and brand influence in the Australian market, thereby driving sales growth.
- Industry Event: Organigram will debut its new product lineup at the Medical Cannabis Symposium in Brisbane, using this platform to introduce its product portfolio to clinicians and industry participants, further solidifying its leadership position in the medical cannabis sector.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Organigram Secures CAD 65.2 Million Investment
- Investment Confirmation: Organigram Global Inc. confirmed a CAD 65.2 million private placement investment from a subsidiary of British American Tobacco, indicating strengthened financial health and increased market confidence.
- Financing Details: The financing includes the subscription of 14,027,074 shares at CAD 3.00 per share (totaling CAD 42.08 million) and the exercise of top-up rights for 9,897,356 shares at CAD 2.335854 per share (totaling CAD 23.12 million), culminating in gross proceeds of CAD 65.2 million.
- Market Reaction: Following the investment confirmation, Organigram's stock rose 8.70% in Thursday's premarket trading, reflecting investor optimism about the company's future, while the stock is currently trading 4.8% above its 20-day simple moving average.
- Earnings Outlook: Organigram is set to provide its next financial update on May 11, 2026, with EPS estimates dropping from 22 cents to a loss of 1 cent, while revenue estimates are expected to rise from CAD 45.70 million to CAD 54.67 million, indicating potential value opportunities.
See More
British American Tobacco Invests C$65.2M in Organigram Acquisition
- Investment Scale: British American Tobacco's C$65.2M private placement for Organigram's Sanity Group acquisition underscores its commitment to emerging markets, likely enhancing Organigram's competitive position.
- Share Subscription: Under the agreement, BAT will subscribe to approximately 14.02 million Organigram shares at C$3.00 each, generating about C$42.1M, which will further solidify its equity stake in Organigram.
- Use of Funds: The proceeds from this financing will be combined with existing cash and up to C$60M in credit facilities from ATB Financial to fund the cash portion of the Sanity acquisition and cover transaction costs, ensuring a smooth acquisition process.
- Market Reaction: Organigram's shares rose by 4.35% in premarket trading, reflecting positive market sentiment towards this investment and acquisition plan, which may enhance the company's long-term growth potential.
See More
Organigram Enters Subscription Agreement with BAT for Sanity Acquisition
- Significant Financing: Organigram's subscription agreement with BAT will provide the company with a total of C$65 million in funding, including the purchase of 14,027,074 shares at C$3.00 each, indicating strong market support for its acquisition of Sanity Group.
- Equity Structure Adjustment: BAT will receive 2,353,379 common shares and 21,571,051 preferred shares in this transaction, with the preferred shares convertible into common shares without exceeding a 30% ownership threshold, ensuring BAT's influence within the company.
- Regulatory Approval Requirements: The acquisition and private placement investment are subject to multiple regulatory approvals, including from the Toronto Stock Exchange and Organigram's shareholders, highlighting the complexity of the transaction and its implications for corporate governance.
- Strategic Investment Intent: Through this transaction, BAT further solidifies its investment in Organigram, reflecting its long-term optimism about the cannabis market and potentially increasing its control over the company by adding board members.
See More
Organigram Proposes Acquisition of Sanity Group
- Acquisition Overview: Organigram plans to acquire German cannabis company Sanity Group for €113.4 million (approximately $134 million), comprising €80 million in cash and €33.4 million in Organigram shares, significantly enhancing its position in the global cannabis market.
- Financing Strategy: The acquisition will be financed through a combination of cash on hand, proceeds from a new credit facility, and expected equity investment, with Organigram in talks for a CAD 65.2 million (around $47.8 million) investment from British American Tobacco to support the cash component of the deal.
- Strategic Importance: Paolo De Luca, Chief Strategy Officer, stated that by combining strengths with Sanity, Organigram will accelerate growth in key European markets and create substantial value for shareholders, thereby strengthening its competitive edge in the world's largest federally legal cannabis markets.
- Market Performance Analysis: Despite a 7.09% increase in premarket trading to $1.36, Organigram's stock remains below its 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, with key support at $1.00 and resistance at $1.50.
See More
